These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11902305)

  • 21. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
    Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P
    Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960
    [No Abstract]   [Full Text] [Related]  

  • 22. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 23. [Stimulation of fetal hemoglobin production in children with sickle cell anemia].
    de Montalembert M
    Arch Pediatr; 1996 Mar; 3(3):207-9. PubMed ID: 8785555
    [No Abstract]   [Full Text] [Related]  

  • 24. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 25. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
    J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ
    Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract]   [Full Text] [Related]  

  • 29. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 33. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic modulation of fetal hemoglobin.
    Steinberg MH; Rodgers GP
    Medicine (Baltimore); 2001 Sep; 80(5):328-44. PubMed ID: 11552087
    [No Abstract]   [Full Text] [Related]  

  • 35. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 36. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
    Shetty AK; Kumar SR; Gedalia A; Warrier RP
    J Pediatr Hematol Oncol; 1998; 20(4):335-7. PubMed ID: 9703008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
    de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
    J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
    Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT
    Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
    Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B
    Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.